Loading...
Initial Testing of the MDM2 Inhibitor RG7112 by the Pediatric Preclinical Testing Program
BACKGROUND: RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively lo...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2012
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3495996/ https://ncbi.nlm.nih.gov/pubmed/22753001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24235 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|